In May 2023, a novel tracer, flotufolastat F 18 (POSLUMA®), formerly referred to as 18 F-rhPSMA-7.3, was approved by the FDA as a PSMA-PET tracer for the staging of prostate cancer patients with a ...
In November 2023, the United States Food and Drug Administration (FDA) approved enzalutamide, with or without concurrent leuprolide therapy, for conventional imaging-defined non-metastatic ...
is honored to present coverage from the 4th Friends of Israel Urological Symposium (FOIU) held in Tel Aviv, Israel. The 2018 Symposium creates an unparalleled opportunity for local and international ...
(UroToday.com) The 2024 American Society of Clinical Oncology (ASCO) annual meeting featured a session on prostate cancer, and a presentation by Dr. Martin Schoen discussing a comparison of outcomes ...
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
(UroToday.com) The 2024 American Urological Association (AUA) annual meeting held in San Antonio, TX between May 3 and May 6, 2024, was host to the AUA-IBCG Bladder Cancer Forum. Drs. Stephen Williams ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback